TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22999730

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) at 60% of peak oxygen consumption, 2 times weekly for 10 years.
Number of subjects: 123

Group type: COMPARATOR
Intervention: Non-trained group (NT) did not exercise formally.
Number of subjects: 123
Study: 19443681

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg once daily with triphasic oral contraceptive (OC)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg once daily with triphasic oral contraceptive (OC)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo with triphasic oral contraceptive (OC)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Etoricoxib (both dosages) with triphasic oral contraceptive (OC)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Etoricoxib and OC
Number of subjects: 79
Study: 17302652

Group type: EXPERIMENTAL
Intervention: Comprehensive vision and eye examinations with subsequent treatment (new eyeglasses, referrals for occupational therapy, glaucoma management, cataract surgery)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Comprehensive vision and eye examinations with subsequent treatment
Number of subjects: 616
Study: 15346658

Group type: COMPARATOR
Intervention: Transdermal 17beta‐estradiol 0.05 mg/day
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 140
Study: 11996209

Group type: EXPERIMENTAL
Intervention: Formulation A (0.02 mg ethinylestradiol and 0.1 mg levonorgestrel)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Formulation B (0.03 mg ethinylestradiol and 0.15 mg levonorgestrel)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Formulation A
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Formulation B
Number of subjects: 67
Study: 9822496

Group type: EXPERIMENTAL
Intervention: Prepidil with immediate oxytocin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cervidil
Number of subjects: 150
Study: 8004298

Group type: EXPERIMENTAL
Intervention: Eucapnic Voluntary Hyperventilation (EVH)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Eucapnic Voluntary Hyperventilation (EVH) after Methacholine Inhalation Challenge (MIC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Methacholine Inhalation Challenge (MIC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Methacholine Inhalation Challenge (MIC) after Eucapnic Voluntary Hyperventilation (EVH)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Subset of patients most sensitive to methacholine (PD20 < 0.1 breath unit) after Eucapnic Voluntary Hyperventilation (EVH)
Number of subjects: 16
Study: 2529798

Group type: EXPERIMENTAL
Intervention: Loratadine 5 mg plus pseudoephedrine 120 mg twice a day
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 1096122

Group type: EXPERIMENTAL
Intervention: Clotrimazole cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolnaftate cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nystatin cream
Number of subjects: 0
Study: 31303397

Group type: EXPERIMENTAL
Intervention: Mindfulness Awareness Program (MAP)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Health Education Program (HEP)
Number of subjects: 55
Study: 28677999

Group type: EXPERIMENTAL
Intervention: RT plus black mulberry molasses
Number of subjects: 80

Group type: COMPARATOR
Intervention: RT
Number of subjects: 80
Study: 24861717

Group type: COMPARATOR
Intervention: Human Patient Simulator (HAL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Human Patient Simulator (SimMan)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 80
Study: 23863328

Group type: EXPERIMENTAL
Intervention: Rabeprazole 0.5‐ or 1.0‐mg/kg granule formulation for 12 weeks (5 or 10 mg for low-weight cohort; 10 or 20 mg for high-weight cohort)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Rabeprazole 0.5‐ or 1.0‐mg/kg granule formulation for 12 weeks
Number of subjects: 108
Study: 21823172

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (LAI) (150 mg/2 weeks, 405 mg/4 weeks, or 300 mg/2 weeks)
Number of subjects: 921

Group type: COMPARATOR
Intervention: Oral olanzapine (10, 15, or 20 mg/day)
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Both treatments (LAI and oral olanzapine)
Number of subjects: 921
Study: 19635216

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine infusion under general anesthesia and 0.1 mg/kg ketamine for 24 hours post-surgery
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine infusion under general anesthesia and 0.05 mg/kg ketamine for 24 hours post-surgery
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine infusion under general anesthesia and 0.01 mg/kg ketamine for 24 hours post-surgery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal saline only (control group)
Number of subjects: 200
Study: 16947094

Group type: EXPERIMENTAL
Intervention: Intermittent diazepam prophylaxis (n = 68)
Number of subjects: 139

Group type: COMPARATOR
Intervention: No prophylaxis (n = 71)
Number of subjects: 139
Study: 15587293

Group type: EXPERIMENTAL
Intervention: Educational strategy promoting participation of three phases (homework, discussion in small groups, plenary session)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational strategy promoting participation of two phases (homework and plenary session)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 0
Study: 11006205

Group type: EXPERIMENTAL
Intervention: Transvaginal intracardiac embryo puncture
Number of subjects: 149
Study: 9348834

Group type: EXPERIMENTAL
Intervention: Substance abuse education intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (promotion workshop without substance abuse component)
Number of subjects: 88
Study: 1490448

Group type: EXPERIMENTAL
Intervention: Spiral volumetric computed tomography (SVCT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dynamic incremental computed tomography (DICT)
Number of subjects: 100
Study: 3895889

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Erythromycin-sulfisoxazole
Number of subjects: 145
Study: 31294485

Group type: EXPERIMENTAL
Intervention: Refutation response
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Attack response
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Denial response
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Rumor responses (refutation, denial, attack the attacker)
Number of subjects: 915
Study: 30475868

Group type: EXPERIMENTAL
Intervention: Bayesian additive regression tree model predicting university GPA
Number of subjects: 109
Study: 28440024

Group type: EXPERIMENTAL
Intervention: Immediate loading of 2 reduced-diameter implants with locator-analog attachments
Number of subjects: 25

Group type: COMPARATOR
Intervention: Delayed loading of 4 reduced-diameter implants with locator-analog attachments
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Immediate loading of 2 implants
Number of subjects: 25
Study: 25486131

Group type: EXPERIMENTAL
Intervention: Extended-release phentermine and topiramate
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 328
Study: 24048296

Group type: EXPERIMENTAL
Intervention: Practice nurse led telephone coaching intervention (8 telephone and 1 face to face coaching episodes per patient)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Usual primary care (control group)
Number of subjects: 473
Study: 20068559

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (1 g tablet after breakfast and 1 g tablet after dinner for 24 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet alone (control group)
Number of subjects: 0
Study: 18855809

Group type: EXPERIMENTAL
Intervention: On-site primary care
Number of subjects: 582
Study: 16642607

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with routine western medicine (Mannitol, Nifedipine, and Ceftriaxone sodium) for 10 days, starting 9 days after operation.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine western medicine (Mannitol, Nifedipine, and Ceftriaxone sodium).
Number of subjects: 100
Study: 12841698

Group type: EXPERIMENTAL
Intervention: Fundal pressure during cesarean delivery
Number of subjects: 84

Group type: COMPARATOR
Intervention: No fundal pressure during cesarean delivery
Number of subjects: 84
Study: 10493335

Group type: EXPERIMENTAL
Intervention: PncD vaccine (3 or 10 microg of pneumococcal PS serotypes 6B, 14, 19F, and 23F conjugated to diphtheria toxoid)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PncT vaccine (3 or 10 microg of pneumococcal PS serotypes 6B, 14, 19F, and 23F conjugated to tetanus protein)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PncD and PncT vaccines
Number of subjects: 40
Study: 8905945

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg intravenous (group O)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no ondansetron, group C)
Number of subjects: 12
Study: 1831016

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg IV)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 71
Study: 7016322

Group type: EXPERIMENTAL
Intervention: Melphalan (L-PAM)
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: Melphalan (L-PAM) + 5-FU (PF)
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: PF + Methotrexate (MTX) (PMF)
Number of subjects: 1548

Group type: COMPARATOR
Intervention: PF
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: PMF
Number of subjects: 1548
Study: 31183750

Group type: EXPERIMENTAL
Intervention: Strength training with daily protein supplementation for 10 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 31579326

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided rectus sheath block with 0.25% ropivacaine (0.5 ml/kg per side)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Local anesthetic infiltration of the surgical field with 0.5% ropivacaine (0.4 ml/kg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study: 27935465

Group type: EXPERIMENTAL
Intervention: Self-hypnosis (performed at least 10 times a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study: 25467200

Group type: EXPERIMENTAL
Intervention: Combined lumbopelvic motor control and progressive hip strengthening exercise therapy programme
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lumbopelvic motor control exercise programme
Number of subjects: 80
Study: 23150693

Group type: EXPERIMENTAL
Intervention: Active subjects
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sedentary subjects
Number of subjects: 31
Study: 22046719

Group type: EXPERIMENTAL
Intervention: Cognitive countermeasures (information removal technique)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No countermeasure (control group)
Number of subjects: 23
Study: 19196472

Group type: EXPERIMENTAL
Intervention: PolyGlycoplex (PGX) supplementation at a maximum dose of 10 g per day for 21 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PolyGlycoplex (PGX) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17027571

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day)
Number of subjects: 70
Study: 12751275

Group type: EXPERIMENTAL
Intervention: Calcium-fortified orange juice
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Orange juice without calcium fortification
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control arm (no juice)
Number of subjects: 16
Study: 11206864

Group type: EXPERIMENTAL
Intervention: Sumatriptan (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rizatriptan (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rizatriptan (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8455664

Group type: EXPERIMENTAL
Intervention: Ondansetron plus metopimazine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ondansetron alone
Number of subjects: 30
Study: 3095111

Group type: EXPERIMENTAL
Intervention: Verapamil 3 X 40 mg X d‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Verapamil 3 X 80 mg X d‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Verapamil 3 X 120 mg X d‐1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30077288

Group type: EXPERIMENTAL
Intervention: DEX (dexmedetomidine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol-remifentanil (control group)
Number of subjects: 40
Study: 27379911

Group type: EXPERIMENTAL
Intervention: Salbutamol inhalation (5 mg salbutamol sulfate, 1 mL saline + 1 mL salbutamol, nebulized for 10 minutes)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Saline inhalation (2 mL nebulized normal saline)
Number of subjects: 23
Study: 23970206

Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine/nevirapine (group 1)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: tenofovir/lopinavir/ritonavir (group 2)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine/zidovudine (group 3)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine/efavirenz (group 4)
Number of subjects: 119
Study: 22436797

Group type: EXPERIMENTAL
Intervention: Risperidone 0.5 mg every 12 hours (n = 51)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo every 12 hours (n = 50)
Number of subjects: 101
Study: 20513750

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy titration to maximal tolerated dose
Number of subjects: 138
Study: 18791928

Group type: EXPERIMENTAL
Intervention: AHCC (3.0 g/day for 4 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 15908270

Group type: EXPERIMENTAL
Intervention: Mannitol infusion
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Conservative therapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Renal transplantation
Number of subjects: 36
Study: 12050274

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg/d)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Risperidone (4 mg/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10505899

Group type: EXPERIMENTAL
Intervention: Nurse home visiting programme for vulnerable families with newborns
Number of subjects: 181
Study: 8648287

Group type: EXPERIMENTAL
Intervention: Reorganizing clue provided post-learning to categorize a second, interfering list.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reorganizing clue provided post-learning during serial recall of an initial list of letters.
Number of subjects: 0
Study: 1306421

Group type: EXPERIMENTAL
Intervention: Celaskon effervescens Spofa at a dose of 500 mg/day/person
Number of subjects: 140
Study: 3882063

Group type: EXPERIMENTAL
Intervention: cyclosporin
Number of subjects: 230

Group type: COMPARATOR
Intervention: azathioprine
Number of subjects: 230
Study: 30630451

Group type: EXPERIMENTAL
Intervention: Graf's fixation device
Number of subjects: 117

Group type: COMPARATOR
Intervention: Manual fixation by parents
Number of subjects: 117
Study: 30424770

Group type: EXPERIMENTAL
Intervention: Perioperative high PEEP (8 cmH2O) with systematic recruitment maneuvers and ultra-protective ventilation during CPB.
Number of subjects: 494

Group type: COMPARATOR
Intervention: Low levels of PEEP (2 cmH2O) with no recruitment maneuvers and continuous positive airway pressure during CPB (2 cmH2O).
Number of subjects: 494
Study: 26704806

Group type: EXPERIMENTAL
Intervention: Arthrotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arthroscopy
Number of subjects: 0
Study: 24734247

Group type: EXPERIMENTAL
Intervention: High-intensity strength training
Number of subjects: 473
Study: 21566200

Group type: EXPERIMENTAL
Intervention: CS‐0777 0.1 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CS‐0777 0.3 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CS‐0777 1.0 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CS‐0777 2.5 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CS‐0777 (all doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CS‐0777 (2.5 mg)
Number of subjects: 24
Study: 20332306

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 3608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3608

Group type: EXPERIMENTAL
Intervention: Combined (Finasteride and Placebo)
Number of subjects: 3608
Study: 18541793

Group type: EXPERIMENTAL
Intervention: TIA alone as a qualifying event
Number of subjects: 57

Group type: COMPARATOR
Intervention: Stroke alone as a qualifying event
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Presence of cerebral infarct on baseline neuroimaging
Number of subjects: 57
Study: 15955184

Group type: EXPERIMENTAL
Intervention: Enhanced Search AV (ESAV) parameters
Number of subjects: 30

Group type: COMPARATOR
Intervention: Default Search AV (KSAV) parameters
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both arms (ESAV and KSAV)
Number of subjects: 30
Study: 11799082

Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 28

Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 28
Study: 10529261

Group type: EXPERIMENTAL
Intervention: Isolated limb perfusion (ILP) with melphalan
Number of subjects: 65

Group type: COMPARATOR
Intervention: Wide excision only
Number of subjects: 65
Study: 7793541

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 0
Study: 1522839

Group type: EXPERIMENTAL
Intervention: 600 mg of mifepristone
Number of subjects: 800

Group type: COMPARATOR
Intervention: 100 micrograms of ethinyl estradiol and 1 mg of norgestrel (standard therapy)
Number of subjects: 800
Study: 6398430

Group type: EXPERIMENTAL
Intervention: Desferrioxamine (30 mg/kg body weight/day for 1 week every 3 months)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 mg twice/wk orally)
Number of subjects: 40
Study: 31817691

Group type: EXPERIMENTAL
Intervention: Plant-based protein blend #1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Plant-based protein blend #2
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Plant-based protein blend #3
Number of subjects: 18

Group type: COMPARATOR
Intervention: Whey Protein Isolate (WPI)
Number of subjects: 18
Study: 29353627

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no reflexology)
Number of subjects: 60
Study: 26950347

Group type: EXPERIMENTAL
Intervention: EBIKE training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Run training
Number of subjects: 12
Study: 24970721

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21883097

Group type: EXPERIMENTAL
Intervention: Perampanel (up to 4 mg/day, dosed once- or twice-daily) in study 206
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Perampanel (up to 12 mg/day, once-daily) in study 208
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo in study 206
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo in study 208
Number of subjects: 201
Study: 20573972

Group type: EXPERIMENTAL
Intervention: LICI applied to the left DLPFC in 30 subjects
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TMS-EEG indices of CI
Number of subjects: 36

Group type: COMPARATOR
Intervention: EEG measures of LICI
Number of subjects: 36
Study: 18156659

Group type: EXPERIMENTAL
Intervention: Protein enriched recovery feeding (218 g protein, 435 g carbohydrate, 79 g fat)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isocaloric control (34 g protein, 640 g carbohydrate, 79 g fat)
Number of subjects: 10
Study: 16299640

Group type: EXPERIMENTAL
Intervention: Psychiatrist telephone advice
Number of subjects: 669

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 669
Study: 11898004

Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 560

Group type: COMPARATOR
Intervention: 1% hydrocortisone acetate ointment
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment and 0.1% tacrolimus ointment
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Tacrolimus treatment groups
Number of subjects: 560
Study: 10202314

Group type: EXPERIMENTAL
Intervention: Dry-powder inhaler (DPI) with 200 microg salbutamol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dry-powder inhaler (DPI) with 1,000 microg salbutamol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) with spacer and 1,000 microg salbutamol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nebulizer (NEB) with 1,000 microg salbutamol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7554879

Group type: EXPERIMENTAL
Intervention: Reading by 5 dermatologists
Number of subjects: 40
Study: 2157469

Group type: EXPERIMENTAL
Intervention: nifedipine 10 mg t.i.d. for six weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: tiapamil 300 b.i.d. for six weeks
Number of subjects: 18
Study: 7288605

Group type: EXPERIMENTAL
Intervention: Naloxone (0.2, 0.4 and 0.8 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Morphine (5 and 10 mg)
Number of subjects: 6
Study: 31276585

Group type: EXPERIMENTAL
Intervention: IL‐18
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL‐2rα and IL‐6R
Number of subjects: 0
Study: 27685251

Group type: EXPERIMENTAL
Intervention: Bloodletting with lifestyle and diet advice (LFDA)
Number of subjects: 274

Group type: COMPARATOR
Intervention: LFDA only (Control)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Bloodletting with LFDA
Number of subjects: 274
Study: 27093204

Group type: EXPERIMENTAL
Intervention: MMC Hydrogel (0.8 mg MMC with 1cc water and propylene glycol)
Number of subjects: 40